A German biotech company has reported encouraging clinical trial results for an antidepressant paired with a genetic test that identifies patients most likely to benefit from the drug.
Hans Eriksson, chief medical officer of Munich-based HMNC Brain Health, called the study of its BH-200 drug in 338 patients with major depression “a major step forward in precision psychiatry”.
Participants were divided into three groups according to the genetic profile of hormones produced in their brain in response to stress. Although treatment with BH-200 improved everyone’s symptoms, one group — accounting for 27 per cent of patients — benefited significantly more than the others.
您已阅读26%（672字），剩余74%（1930字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。